# Axsome Therapeutics, Inc. clinical trials: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Axsome Therapeutics, Inc. as lead sponsor, 9 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Axsome Therapeutics, Inc.: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/axsome-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 9
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 19, 2026 | NCT07773883 | An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD | Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | ADHD | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773883) |
| August 14, 2026 | NCT07766655 | Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT) | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Smoking Cessation | 705 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766655) |
| July 21, 2026 | NCT07717892 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | ADHD | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717892) |
| July 21, 2026 | NCT07717879 | Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | ADHD | 468 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717879) |
| June 9, 2026 | NCT07637162 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia | Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | Fibromyalgia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637162) |
| March 20, 2026 | NCT07484217 | Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484217) |
| February 9, 2026 | NCT07398417 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Fibromyalgia | 620 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398417) |
| March 17, 2025 | NCT06878976 | A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder | Axsome Therapeutics, Inc. | Phase 3 | Enrolling by invitation | Binge-Eating Disorder | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06878976) |
| December 16, 2024 | NCT06736509 | An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2... | Axsome Therapeutics, Inc. | Phase 3 | Terminated | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736509) |
| August 23, 2024 | NCT06568367 | Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Excessive Sleepiness, Shift-work Disorder | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06568367) |
| May 14, 2024 | NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | Axsome Therapeutics, Inc. | Phase 3 | Recruiting | Binge-Eating Disorder | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06413433) |
| May 14, 2024 | NCT06413420 | SUNOSI® (Solriamfetol) Pregnancy Registry | Axsome Therapeutics, Inc. | Observational | Recruiting | Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring | 1,731 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06413420) |
| April 11, 2024 | NCT06360419 | Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol | Axsome Therapeutics, Inc. | Phase 3 | Completed | Major Depressive Disorder | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06360419) |
| January 25, 2024 | NCT06223880 | A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Axsome Therapeutics, Inc. | Phase 4 | Recruiting | Major Depressive Disorder | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06223880) |
| August 2, 2023 | NCT05972044 | A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) | Axsome Therapeutics, Inc. | Phase 3 | Completed | ADHD | 516 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05972044) |
| September 28, 2022 | NCT05557409 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation | Axsome Therapeutics, Inc. | Phase 3 | Completed | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05557409) |
| September 22, 2022 | NCT05550207 | Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) | Axsome Therapeutics, Inc. | Phase 3 | Completed | Migraine | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05550207) |
| November 9, 2021 | NCT05113745 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) | Axsome Therapeutics, Inc. | Phase 3 | Completed | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05113745) |
| September 28, 2021 | NCT05059223 | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy | Axsome Therapeutics, Inc. | Phase 3 | Completed | Narcolepsy, Cataplexy, Excessive Daytime Sleepiness | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05059223) |
| August 17, 2021 | NCT05008341 | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration | Axsome Therapeutics, Inc. | Phase 1 | Completed | Narcolepsy, Obstructive Sleep Apnea, Excessive Daytime Somnolence, Excessive Sleepiness, Postpartum | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05008341) |
| July 21, 2021 | NCT04971291 | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients | Axsome Therapeutics, Inc. | Phase 2 | Unknown | Major Depressive Disorder, Treatment Resistant Depression | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04971291) |
| July 1, 2021 | NCT04947553 | A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation | Axsome Therapeutics, Inc. | Phase 3 | Completed | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04947553) |
| March 15, 2021 | NCT04797715 | Assessing Clinical Outcomes in Alzheimer's Disease Agitation | Axsome Therapeutics, Inc. | Phase 3 | Completed | Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04797715) |
| March 9, 2021 | NCT04789174 | Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study | Axsome Therapeutics, Inc. | Phase 4 | Completed | Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04789174) |
| November 18, 2020 | NCT04634669 | Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) | Axsome Therapeutics, Inc. | Phase 2 | Terminated | Treatment Resistant Depression, Major Depressive Disorder | 181 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04634669) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 27 |
| Phase 4 | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Recruiting | 9 |
| Enrolling by invitation | 3 |
| Unknown | 3 |
| Terminated | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Depressive Disorder, Major | 10 |
| Disorders of Excessive Somnolence | 7 |
| Depression | 7 |
| Narcolepsy | 5 |
| Depressive Disorder, Treatment-Resistant | 5 |
| Alzheimer Disease | 5 |
| Psychomotor Agitation | 5 |
| Attention Deficit Disorder with Hyperactivity | 4 |
| Migraine Disorders | 4 |
| Cataplexy | 3 |
| Sleep Apnea, Obstructive | 3 |
| Binge-Eating Disorder | 2 |
| Fibromyalgia | 2 |
| Hyperalgesia | 2 |
| Sleep Initiation and Maintenance Disorders | 1 |
| Sleep Disorders, Circadian Rhythm | 1 |
| Osteoarthritis, Knee | 1 |
| Osteoarthritis | 1 |
| Smoking Cessation | 1 |
| Smoking | 1 |
| Complex Regional Pain Syndromes | 1 |
| Reflex Sympathetic Dystrophy | 1 |
| Chronic Pain | 1 |
| Depressive Disorder | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pubs in the United States](https://specstream.ai/data/businesses/pubs/united-states)
- [Security companies in the United States](https://specstream.ai/data/businesses/security-companies/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
